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Abstract
 
Antigens that are tumor specific yet retained by tumor cells despite tumor progression offer
stable and specific targets for immunologic and possibly other therapeutic interventions.
 
Therefore, we have studied two CD4
 
 
 
 T cell–recognized tumor-specific antigens that were
retained during evolution of two ultraviolet-light–induced murine cancers to more aggressive
growth. The antigens are ribosomal proteins altered by somatic tumor-specific point muta-
tions, and the progressor (PRO) variants lack the corresponding normal alleles. In the first tu-
mor, 6132A-PRO, the antigen is encoded by a point-mutated L9 ribosomal protein gene.
The tumor lacks the normal L9 allele because of an interstitial deletion from chromosome 5.
In the second tumor, 6139B-PRO, both alleles of the L26 gene have point mutations, and
each encodes a different tumor-specific CD4
 
 
 
 T cell–recognized antigen. Thus, for both L9
and L26 genes, we observe “two hit” kinetics commonly observed in genes suppressing tumor
growth. Indeed, reintroduction of the lost wild-type L9 allele into the 6132A-PRO variant
 
suppressed the growth of the tumor cells in vivo
 
.
 
 Since both L9 and L26 encode proteins es-
sential for ribosomal biogenesis, complete loss of the tumor-specific target antigens in the ab-
sence of a normal allele would abrogate tumor growth.
 
Key words: ribosomal proteins • loss of heterozygosity • point mutation • CD4-positive T 
lymphocytes • tumor escape
 
Introduction
 
Tumor antigens are encoded by genes that are either normal
but aberrantly expressed or overexpressed (1, 2), or altered
as the result of cancer-specific somatic mutations (3–5). As
an example of the latter, in a murine tumor designated
6132A, a somatic point mutation in the ribosomal protein
 
L9 gives rise to an immunodominant CD4
 
 
 
 T cell–recog-
nized tumor-specific antigen (3). In some instances, a so-
matic mutation encoding a tumor-specific antigen is be-
lieved to contribute to the development of cancer (4, 6–8).
In other cases, such a mutation has not been linked to the
malignant phenotype but appears to affect a protein essential
for basic cellular functions. For example, the ribosomal pro-
tein L9 is essential for protein synthesis and homozygous de-
 
letion of L9 is lethal in 
 
Drosophila
 
 (9). Another example is
the human homologue of the yeast bet 5 gene which en-
codes a protein that is part of the transport protein particle
involved in ER-to-Golgi transport. A mutation in this
household gene causes a CD8
 
 
 
 T cell–recognized antigen
in a human melanoma (10).
Tumor antigens, whether encoded by normal or mutant
genes, may be lost by more malignant variants that arise
during tumor progression in mice (11–16). Indeed, this
might be expected since loss of antigens may give a selec-
tive survival advantage to a loss variant. It is somewhat sur-
prising then that certain tumor-specific antigens are re-
tained during tumor progression. For example, it was
found many years ago that certain tumor-specific antigens
 
recognized by CD4
 
 
 
 T cells can be retained (17), even
though CD4
 
 
 
 T cells, upon adoptive transfer, can be very
effective in eliminating tumor cells (3, 18, 19); we (20) and
others (21) have shown that this killing occurs by an indi-
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rect mechanism requiring IFN-
 
 
 
. Since these CD4
 
 
 
 T cells
can eliminate MHC class II-negative tumor cells even in
the absence of CD8
 
 
 
 T cells, such an attack may be effec-
tive even when MHC antigens are lost by the tumor cells
during tumor progression. For example, we have shown
previously that CD4
 
 
 
 T cells specific for the mutated form
of L9 can eliminate in vivo MHC class II-negative tumor
cells expressing this antigen, without selection for antigen
loss variants (20). Tumor-specific antigens recognized by
CD8
 
 
 
 T cells can also be retained by variants during pro-
gression even though these antigens are direct targets for T
cell immunity (12), and in one recent study, extensive ef-
forts to select for antigen loss variants of a methylcholan-
threne-induced sarcoma in vitro failed using CD8
 
 
 
 T cells
specific for a tumor antigen (22).
Since tumor progression and the loss of target antigens
represents a major problem for the development of effec-
tive immunotherapies, it is important to understand the
reasons for retention of certain tumor-specific antigens.
UV-induced murine tumors offer a powerful model for
studying antigen loss or retention during tumor progres-
sion. The primary UV-induced murine cancers are often
rejected by normal mice but grow in T cell–deficient mice
(23); these regressor (RE)
 
*
 
 tumors give rise to heritable,
more aggressive (progressor [PRO]) variants, which grow
progressively to kill normal, immunocompetent mice (12,
24). Surprisingly, as many as two-thirds of these UV-
induced PRO variants retain tumor-specific antigens that
are detected by tumor-specific T cell clones on the paren-
tal RE tumors (12). These PRO variants usually grow
faster in T cell–deficient mice than the parental RE tu-
mors, and we have shown that mechanisms other than an-
tigen loss or loss of MHC expression can account for this
PRO phenotype (24, 25).
In this study, we have examined two independently in-
duced murine cancers, 6132A and 6139B, in which CD4
 
 
 
tumor-specific antigens are retained during tumor progres-
sion. We find that the antigens in both PRO variants are
caused by point mutations in genes encoding essential
“household” proteins, but also that neither tumor retains a
normal allele. In 6139B-PRO, we find that both alleles of
the L26 gene are mutant; each is affected by a different mu-
tation and specifies a different CD4
 
 
 
 T cell–recognized an-
tigen. In 6132A-PRO, in which the antigen is encoded by
a mutant ribosomal L9 gene, the second allele is lost. Rein-
troduction of the wild-type (wt)L9 gene by transfection re-
versed 6132A-PRO to a RE phenotype consistent with
the hypothesis that loss of the wt allele favored the PRO
phenotype. Since L9 and L26 are probably essential for
protein synthesis, loss of the normal alleles would explain
the need for continued expression of these mutant genes
encoding tumor-specific antigens in the PRO variants.
 
Materials and Methods
 
Tumor Cell Lines.
 
The derivation of tumors 6132A-RE,
6132B, 6139B-RE, 6139B-PRO-V (in vivo), and 6139B-PRO-T
(in vitro) has been described previously (12, 26).
 
 
 
6132A-RE,
6139B-RE, and 4102-RE are rejected by normal mice, whereas
the variants 6132A-PRO, 6139B-PRO (selected either in vitro
[T] or in vivo [V]), and 4102-PRO grow progressively in the
majority of normal mice. 6139B-PRO-T was selected in vitro by
exposure to tumor-specific CTL; the other PRO variants had
been selected in vivo by normal mice injected with large doses of
the RE tumors (12). This selection leads to the outgrowth of her-
itable variants that regularly grow in the majority of normal mice.
6132A and 6132B are two UV-induced tumors that developed at
different locations in the same mouse. Retention of the unique
CD4
 
 
 
 T cell–recognized 6139B antigen was tested on two dif-
ferent 6139-PRO variants that have lost different unique antigens
recognized by CD8
 
 
 
 T cells. 6132-heart-lung fibroblast (HLF)
and 6139-HLF cells are HLFs derived from the mice in which
the 6132A-RE and 6139B-RE tumors, respectively, developed
originally. Tumor cells and fibroblasts were cultured in DMEM
medium containing 10% fetal bovine serum. Tumor cell lysates
were generated as follows: 6139B-PRO or 4102-PRO cells were
washed with MEM, resuspended at a density of 6–13 
 
 
 
 10
 
7
 
 cells
per milliliter in MEM, and lysed by three cycles of freezing and
thawing; lysates were stored at 4
 
 
 
C.
 
Generation and Analyses of CD4
 
  
 
T Cell Hybridomas
 
.
 
The hy-
bridoma 479H-60, which is specific for the mutant (m)L9 protein
of the 6132A tumor, has been described previously (3). The hy-
bridomas 426H-64 and 425H-26 were generated analogously by
fusing CD4
 
 
 
 T cell lines, specific for 6139B or 4102 tumor cells,
with BW5147. The general methods for the generation and
maintenance of tumor-specific T cell lines, clones, and hybrid-
omas have been described in detail (3). The anti-6139B T cell
hybridoma was generated from immune CD4
 
 
 
 spleen cells that
had been restimulated in vitro with 6139B-PRO cell lysates. The
donor of these spleen cells had rejected 6139B-RE fragments,
was then treated with anti-CD8 antibody, and challenged with a
lethal dose of 6139B-PRO cells. The CD4
 
 
 
 T cell immunity re-
maining after the anti-CD8 treatment was apparently sufficient to
reject the 6139B-PRO tumor cells. The anti–4102-PRO T cell
hybridoma was generated from CD4
 
 
 
 spleen cells of a syngeneic
C3H/HeN mouse that had rejected a 4102-RE tumor challenge.
Antigen-specific stimulation of IL-2 release from the various
hybridomas was determined by measuring the proliferation of the
IL-2–dependent cell line, CTLL-2, as described previously (3).
Tumor cell lysates, fractions thereof (in solution or blotted on ni-
trocellulose), or peptides were added at indicated amounts to hy-
bridomas cultured in the presence of normal syngeneic spleen cells
(as a source of APCs) for 24 h; 0.1 ml of culture supernatant was
then removed and added to CTLL-2 cells which were cultured
for an additional 24 h. Proliferation of CTLL-2 cells was measured
using the 1-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay (3). For some experiments, culture superna-
tants containing monoclonal antibody 10-2-16 anti–I-A
 
k
 
 (27) or
14-4-4S anti–I-E
 
k
 
 (28) were added at the beginning of culture.
 
Vectors and Transfections.
 
For the expression of the various
L9-enhanced green fluorescent protein (EGFP) fusion proteins or
EGFP alone, wtL9 and mL9 cDNAs were fused in frame with
the EGFP gene (CLONTECH Laboratories, Inc.), and these fu-
sion genes or the EGFP gene alone were cloned into the retrovi-
ral MFG vector (29). The plasmids were transfected into the
6132A-PRO cells together with a pSV2neo plasmid using Super-
fect transfection reagent (QIAGEN), and G418-resistant clones
 
*
 
Abbreviations used in this paper:
 
 AcCN, acetonitrile; EGFP, enhanced
green fluorescent protein; FISH, fluorescence in situ hybridization; HLF,
heart-lung fibroblast; m, mutant; PRO, progressor; RE, regressor; RP-
HPLC, reverse-phase high pressure liquid chromatography; RT, reverse
transcription; SCID, severe combined immunodeficient; wt, wild-type. 
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were analyzed for EGFP fluorescence by flow cytometry. Super-
natants of the transfected cell lines contained virus that infected a
small fraction of NIH 3T3 cells, which are highly susceptible to
infection by ecotropic retroviruses. Therefore, we cannot exclude
that the endogenous retrovirus from the transfected cells mobi-
lized the mL9-EGFP, wtL9-EGFP, or EGFP-alone vectors and
contributed to growth inhibition in vivo. However, this is very
unlikely because the effect we observe would still have to be spe-
cific for wtL9-EGFP since mEGFP and EGFP-alone vectors
were used as controls. Furthermore, all in vivo experiments were
done in severe combined immunodeficient (SCID) or nude mice,
so that immunogenicity due to viral protein or EGFP expression
could not influence the results.
 
Protein Purification.
 
Nuclei were prepared from disrupted cul-
tured tumor cells that had been treated twice with 1% Triton
X-100 in RSBI (10 mM Tris-HCl, containing 10 mM NaCl, 3 mM
MgCl
 
2
 
, 300 
 
 
 
g/ml leupeptin, 300 
 
 
 
g/ml aprotinin, and 40 
 
 
 
g/
ml phenylmethylsulfonyl fluoride for 1 h at 4
 
 
 
C. The nuclei re-
covered by centrifugation at 2,000
 
 
 
 
 
g
 
 were incubated twice with
RSBl plus 0.4 M NaCl for 1 h at 4
 
 
 
C, then once with RSBl plus
2 M NaCl overnight at 4
 
 
 
C. This last extraction was centrifuged
at 200,000
 
 
 
 
 
g
 
 for 2–3 h and the supernatant retained. Ribosomes
were prepared as described previously (30). In brief, the superna-
tant of cells disrupted with Nonidet P (NP)-40 was treated with
deoxycholate, then layered on a discontinuous sucrose gradient,
and centrifuged at 100,000
 
  
 
g
 
 for 24 h; the pellet, enriched in ri-
bosomes, was saved and resuspended in 20 mM Tris-HCl, pH
7.6, 5 mM magnesium acetate, 100 mM NH
 
4
 
Cl, 1 mM dithio-
threitol, and 0.2 M sucrose.
To prepare a nuclear extract or ribosomal fraction for either
reverse-phase high pressure liquid chromatography (RP-HPLC)
or SDS-PAGE, the sample was mixed with an equal volume of
UT2 (6 M urea, 10 mM Tris-HCl, pH 8.5, 2% 2-ME) and an
equal volume of 3
 
 
 
 SDS (12% [wt/vol] SDS, 150 mM Tris-
HCl, pH 6.8, 15% [vol/vol] glycerol, 0.03% [wt/vol] bromophe-
nol blue), with additional 2-ME added to a final concentration of
5% (vol/vol); this solution was then incubated at 37
 
 
 
C for 1 h.
This unorthodox combination of denaturants was used because it
was the only way of many we tried which solubilized the anti-
genic activity consistently. For example, high salt nuclear extracts
frequently precipitated in the 0.1% trifluoroacetic acid used for
chromatography.
RP-HPLC was performed on an IBM LC/9533 ternary gradi-
ent liquid chromatograph with a 4.6 mm 
 
 
 
 25 cm C4 column
(Vydac). All HPLC analyses were performed using water and
acetonitrile (AcCN), both acidified with 0.1% (vol/vol) trifluoro-
acetic acid, at a flow rate of 1 milliliter per min; fractions of
1-min duration were collected. Routinely, a sample was loaded
at 20% AcCN in several aliquots of 1 ml each; after the final load-
ing, the concentration of AcCN was increased to 35% using a lin-
ear gradient over the first 10 min, then to 45% over the next 40
min; the sample that was used to obtain amino acid sequence was
loaded at 35% AcCN and eluted, as above, with a 40-min linear
gradient to 45% AcCN. Fractions were dried in a Speed Vac con-
centrator (Savant), resuspended in 40–80 
 
 
 
l of UT2, and placed
at 4
 
 
 
C overnight before using. Fractions were tested for antigen
by blotting on to nitrocellulose, then incubating with the T cell
hybridoma as described previously (3).
Antigen from 6139B-PRO cells, whether from nuclei or
HPLC fractions, was separated by SDS-PAGE using a Tris-tricine
buffer system (31). The resolving gel was 16.5% T, 3% C, and a
spacer gel with 10% T, 3% C was usually included between the
resolving and stacking gels (where T = total acrylamide and C =
 
N, N
 
 
 
methylene bisacrylamide). In addition, 10 mM dithiothrei-
tol was included in the resolving and spacer gels, and 0.2% 2-ME
was added to the cathode and anode buffers. An HPLC fraction
in UT2 was prepared for SDS-PAGE by adding one-half volume
3
 
 
 
 SDS and 2-ME to 5% and incubating at 37
 
 
 
C for 1 h. Elec-
trophoresed proteins were transferred to nitrocellulose at 50–60
mA for 18–24 h in 25 mM Tris, 192 mM glycine, 20% (vol/vol)
methanol, and the nitrocellulose was used in the hybridoma stim-
ulation assays as described previously (3). For obtaining amino
acid sequence, proteins were transferred to PVDF (Pro-Blott;
Applied Biosystems) under the same conditions. Nitrocellulose
and PVDF membranes were stained with Ponceau S.
 
Protein Sequencing.
 
All steps were performed at the Rock-
efeller University Microchemistry Facility. Protein bound to
PVDF was cleaved with trypsin and the fragments eluted and sep-
arated by RP-HPLC. A prominent peak was subjected to Edman
degradation, yielding the sequence.
 
PCR Analyses at the Transcriptional and Genomic Level.
 
Total
RNA was isolated using the Rneasy Kit (QIAGEN) according to
the manufacturer’s manual. For cDNA synthesis, 4 
 
 
 
l of RNA
were reverse transcribed in a total volume of 40 
 
 
 
l, in the pres-
ence or absence (control samples) of 300 U Superscript reverse
transcriptase. Reactions were carried out at 37
 
 
 
C for 90 min, fol-
lowed by incubation for 10 min at 95
 
 
 
C to inactivate the en-
zyme. Genomic DNA was prepared with the blood and cell cul-
ture DNA kit (QIAGEN). All PCR reactions were carried out
under linear, nonlimiting conditions, and 
 
 
 
-actin expression was
used to normalize the amounts of cDNA template. The pseudo-
gene products served as an internal standard for the amount of
genomic DNA template. Parenthetically, the fact that the
pseudogene fragments were only amplified by the wt, but not by
the mutant-specific PCR primers showed that the point mutation
giving rise to the unique 6132A tumor antigen was not found in
any of the L9 pseudogenes. PCR reactions were performed in a
total volume of 100 
 
 
 
l containing 200 
 
 
 
M dNTPs, 50 pM oligo-
nucleotide primers, and 0.3 
 
 
 
l Taq polymerase (Promega). The
number of PCR cycles and restrictive versus nonrestrictive con-
ditions were chosen to allow linear and specific product amplifi-
cation and were determined individually for each primer combi-
nation. The following primers were used. L9 wt: 5
 
 
 
-
ATCAACGTGGAGCTGAGTCTT-3
 
 
 
;
 
 
 
L9 mut: 5
 
 
 
-ATCAA-
CGTGGAGCTGAGTCAT-3
 
 
 
; L9 3
 
 
 
 cDNA: 5
 
 
 
-GGGAAGT-
GAGCGTACACAGACC-3
 
 
 
;
 
 
 
L9 3
 
 
 
 gen.: 5
 
 
 
-CAGTTCCTT-
TCTGTACCCCACC-3
 
 
 
;
 
 
 
5
 
 
 
-
 
 
 
-actin: 5
 
 
 
-GGATGACGATAT-
CGCTGCGCTG-3
 
 
 
; and 3
 
 
 
-
 
 
 
-actin: 5
 
 
 
-GTACTTCAGGGT-
CAGGATACCTC-3
 
 
 
.
For sequence analysis, PCR products were purified using the
PCR purification kit (QIAGEN) and either sequenced directly
or cloned into the vector pSK II Bluescript (Stratagene). Auto-
mated sequencing was performed at the University of Chicago
DNA sequencing facility.
 
Cytogenetic Probes and Analyses.
 
A mouse chromosome 5-spe-
cific digoxigenin-labeled painting probe was obtained from On-
cor, Inc. Fluorescence in situ hybridization (FISH) was per-
formed as described previously (32). The chromosome 5 painting
probe was detected with rhodamine-conjugated, antidigoxigenin
antibodies (Boehringer Mannheim). Chromosomes were identi-
fied by staining with 4,6-diamidino-2phenylindole-dihydrochlo-
ride (DAPI). The L9 probe was a 2.3-kb PCR product amplified
from the murine L9 gene using the following primers: 5
 
 
 
-GC-
GAATTCGAATGGTGAGTAGATGGCTCCCC (located in
the second intron); and 3
 
 
 
-GCGAATTCGCTCATCCGAAG-
CAGTCAGATGC (located in 3
 
 
 
 untranslated region of the mu- 
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rine L9 gene; unpublished data). The underlined sequence repre-
sents an EcoRI-restriction site used for cloning of the PCR-
fragment. Biotin-labeled L9 probe was prepared by nicktransla-
tion using Bio-16-dUTP (Enzo Diagnostics). For fluorescence in
situ chromosomal hybridization, metaphase cells in log phase
growth were prepared from 6132-HLF, 6132A-RE, and 6132A-
PRO cells using standard cytogenetic techniques (33). Hybridiza-
tion of the biotin-labeled L9 probe was detected with fluores-
cein-conjugated avidin (Vector Laboratories).
 
Immunization and Restimulation with Peptides.
 
Peptides were
emulsified with an equal volume of CFA (H37Ra no. 3113-55;
Difco). 
 
 
 
0.05 ml of emulsion was injected into each hind foot of
C3H mice (total dose in 0.1 ml of emulsion per mouse was 40
nmol L26 H
 
→
 
Y, 67 nmol L26 P
 
→
 
S, or 3.3 nmol L9 H
 
→
 
T).
The popliteal lymph nodes were removed 7 or 8 d later and the
cells dispersed and cultured as follows: 10
 
6
 
 lymph node cells and
antigen (see below) in a well of a 96-well plate in 0.2 ml of
DMEM supplemented with 1% fresh syngeneic mouse serum,
glutamine, Hepes or MOPS, 2-ME, and penicillin and streptomy-
cin; nonessential amino acids, nystatin (GIBCO BRL), and genta-
mycin (GIBCO BRL) were added (3). The specificity of CD4
 
 
 
 T
cells and T cell lines for antigen was assessed by thymidine incor-
poration assay. 3 d after restimulation with antigen, 1 
 
 Ci of
[3H]thymidine (Amersham Pharmacia Biotech) was added to each
well, and 24 h later, the cultures were harvested onto glass fiber
filters using a PHD cell harvester (Cambridge Technology). Ra-
dioactivity was measured by liquid scintillation counting.
Results
Retention of CD4  T Cell–recognized Antigens by PRO
Variants. 6132A-RE, 6139B-RE, and 4102-RE are regu-
larly rejected by normal mice, while the PRO variants de-
rived from these tumors kill the majority of normal mice.
PRO variants 6132A-PRO, 6139B-PRO-V, and 4102-
PRO were derived from host selection in vivo, while
6139B-PRO-T was derived by selection using CD8  T
cells in vitro (12, 24). Fig. 1 shows that each of three CD4 
T cell hybridomas, generated from mice immunized against
the three different tumor lineages, responded to lysates of
the parental RE tumor cells and the PRO variants, but did
not respond to tumor cells from unrelated lineages. Thus,
each hybridoma recognized a unique tumor lineage-spe-
cific antigen, which was retained by the PRO variants,
whether a variant was derived by host selection or by selec-
tion with CD8  T cells in vitro.
The CD4  T Cell–recognized Antigen Retained on 6139B-
PRO Is Derived from L26, also a Ribosomal Protein. Our
previous results have shown that the retained antigen on
6132A tumors is a mutant ribosomal protein L9. To begin
to explore the generality of the molecular nature of such
retained antigens, we determined the genetic origins of the
CD4  T cell–recognized antigen retained on a second tu-
mor, 6139B-PRO. The 6139B antigen was found in the
nuclear and ribosomal fractions of disrupted cells and
could be solubilized with 1.2 M NaCl as described in Ma-
terials and Methods. Thus, the nuclear extracts were frac-
tionated by RP-HPLC and the fractions were individually
tested for antigenicity by coculturing them with the
6139B-PRO–specific T cell hybridoma in the presence of
APCs (Fig. 2 A). The antigenic activity was eluted with
24.5% acetonitrile and was fractionated further by SDS-
PAGE. The antigenicity appeared to reside in a band of
molecular mass of  22 kd, as evidenced by T cell Western
blot analysis (Fig. 2 B). These data were used to purify a
larger sample for amino acid sequencing. Edman degrada-
Figure 1. CD4  T cell–recognized unique tumor-specific antigens are retained on PRO variants that develop from RE tumors during tumor progres-
sion. Each lineage of RE tumors and PRO variants expresses a different unique tumor-specific antigen recognized by a CD4  T cell hybridoma. As
probes for antigen expression, we used one previously described CD4  T cell hybridoma specific for a mutated form of the ribosomal protein L9 ex-
pressed by 6132A-PRO (reference 3), left panel, and two new T cell hybridomas derived from mice immunized with 6139B (center panel) or 4102
(right panel). Presence or absence of antigens was assessed by measuring the amount of IL-2 secreted by the hybridomas in response to various concentra-
tions of lysed tumor cells (x axis) as sources of antigen. IL-2 was assayed by growth of CTLL-2 cells and quantified by MTT (y axis) as described previ-
ously (3). The anti-6132A and anti-6139B hybridoma-recognized antigens are both restricted by I-Ek, while the anti-4102 hybridoma recognized antigen
appears to be I-Ak restricted (reference 3, and data not shown).289 Beck-Engeser et al.
tion of an internal fragment of the protein, isolated by
RP-HPLC of an endoproteinase K digest, revealed the se-
quence YVIYIERVOREK, which is identical to the se-
quence of amino acids 78–89 of ribosomal protein L26.
Additional RP-HPLC peaks of the digest were analyzed
by mass spectrometry and had molecular masses of
1517.84, 1443.71, and 1435.71, identical to the predicted
molecular masses of endoproteinase K peptides from L26
(amino acids, 17–28, 52–63, and 90–103, respectively).
Together, this suggested that the ribosomal protein L26
was the recognized antigen.
The 6139B-PRO Tumor Cells Express Two Different mL26
Alleles but Lack a wtL26 Allele. Sequencing L26 cDNA
from the 6139B-PRO-V revealed that there were two dif-
ferent mutant alleles expressed in the PRO variants but no
wt sequences. One mutation was caused by a C to T nu-
cleotide substitution at position 286 causing a histidine to
tyrosine substitution at amino acid 96; the other mutation
was caused by a C to T nucleotide substitution at position
64 causing a proline to serine substitution at amino acid 22
(Fig. 2 C). The wt allele was not expressed, but the absence
of this allele could have been caused by either transcrip-
tional silencing or loss of the wt allele. Therefore, we de-
termined the genomic structure of the murine L26 gene
(unpublished data) and designed a oligonucleotide primer
that amplified an L26 gene fragment containing one intron.
This allowed us to distinguish the active (i.e., expressed)
L26 alleles from the transcriptionally silent L26 pseudo-
genes that are abundant in the murine genome and lack in-
trons. The larger intron-containing L26 PCR fragment
(3.2 kb) was then cloned and sequenced; again, only two
different mL26 alleles and no wtL26 alleles were detected
(Table I). This indicated that no wtL26 gene remained in
the 6139B-PRO tumor cells. No mutations were detected
in clones from two PCR reactions of cDNA of the autolo-
gous 6139-HLF fibroblasts derived from nonmalignant
heart-lung tissue of the mouse of tumor origin (data not
shown). This suggested that the observed mutations were
of somatic tumor-specific origin. The phylogenetic conser-
vation of the amino acids affected by the two L26 point
mutations is shown in Table II. Furthermore, as could be
expected, the two mutations were detected in 6139B-
PRO only in the expressed L26 genes but not in L26
pseudogenes (Table I). In the parental 6139B-RE tumor,
mostly the H→Y mutation was discovered (Table I). The
P→S mutation was also found, but less frequently, and wt
sequences were found in the expressed L26 gene as well.
Since the 6139B-RE DNA used for sequencing came from
an uncloned primary 14-d-old bulk culture of the original
6139B tumor, we cannot distinguish between the possibil-
Figure 2. Molecular analysis of the CD4  T cell–recognized antigen from 6139B-PRO. (A) RP-HPLC
fractions of a nuclear extract of 6139B-PRO (solid line without symbols, absorbance scale: left y axis) were
tested for antigenic activity using the anti-6139B-PRO T cell hybridoma, secreted IL-2 was measured by
growth of CTLL-2 cells, quantified by MTT assay (line with filled circles, scale: right y axis). (B) The antigenic
HPLC fractions were separated by SDS-PAGE and the antigenic fractions were determined by T cell Western blot analysis using the T cell hybridoma and
MTT assay. Positive and negative controls are at the top of the panel, numbers within the panel show locations of molecular weight markers. (C) Two tu-
mor-specific somatic mutations (6139B-PRO P/S, a proline to serine substitution, and 6139B-PRO H/Y a histidine to tyrosine substitution) were found,
each in a different 6139B tumor cell allele; both mutations were lacking in the autologous control sequence derived from normal cells from the mouse of
tumor origin (6139B-HLF).290 Allelic Loss in Tumor Escape: Retention of Essential Mutant Antigens
ity that some of the 6139B-RE tumor cells still retained the
wt allele (as observed in 6132A-RE) and/or that some
nonmalignant fibroblasts from the tumor stroma survived
the adaptation and gave rise to the wtL26 sequences.
The mL26 Genes Encode Two Different CD4  T Cell–rec-
ognized Antigens. The results of DNA sequencing of
cDNA from the 6139B-PRO cells suggested that there
might be two mutant ribosomal protein L26 antigens, one
containing a proline to serine mutation at position amino
acid 22 and the other containing histidine to tyrosine mu-
tation at amino acid position 96. To test this, we synthe-
sized a peptide of 25 residues centered on position 22 and
containing either proline (P) or serine (S) at this point and a
25 residue peptide centered on position 96 and containing
either histidine (H) or tyrosine (Y) at this position. The
anti–6139B-PRO CD4  T cell hybridoma had been de-
rived from spleen cells of a 6139B-RE immunized, CD8-
depleted mouse that had rejected a subsequent lethal
6139B-PRO tumor challenge. This hybridoma specifically
responded to the H→Y mL26 peptide with no detectable
crossreactivity to the wt peptide or the P→S mutant pep-
tide (Fig. 3 A). To determine whether the two mL26 pep-
tides were similarly immunogenic, normal syngeneic mice
were immunized. A series of pilot experiments (data not
shown) established that the optimal amounts of antigen in
vivo were 33 nmol of the P→S mL26 peptide or 20 nmol
Table II. Phylogenetic Conservation of the Amino Acids Affected by the Two L26 Point Mutations in 6139B Tumor Cells
Sequence Description
HFNASSHIRR
↑
6139B tumor cells
HFNAPSHIRR 6139B normal fibroblasts
HFNAPSHIRR human, mouse, chick
HFNAPSHIRR C. elegans
APS S. cerevisiae, S. pombe, Z. mays
AP Haroarcula marismortui
NAP Pyrococcus horikoshii
FNAP Methanococcus jannaschii
REKANGTTVYVGIHPSK
↑
6139B tumor cells
REKANGTTVHVGIHPSK 6139B normal fibroblasts
REKANGTTVHVGIHPSK human, mouse, chick
REKANG TVH GIHPSK C. elegans
One mutation P→S affects an extremely conserved residue and may destroy the function of the ribosomal protein L26 completely. The other
mutation H→Y affects an amino acid that is less conserved, i.e., “only” down to C. elegans.
Table I. Active L26 Genes in the 6139B-PRO Tumor Are Mutant and Lack a wt Allele, but There Are no Mutations in the L26 
Pseudogenes of this Tumor
Number of mutant or wtL26 sequences per number of sequences analyzed
Source of sequenced
L26 DNA Mutant sequences
Tumor Type of DNA H→YP →S wt sequences
%
6139B-PRO cDNA 23/73 50/73 0/73  (0)
active gene  7/10 3/10 0/10 (0)
pseudogene 0/10 0/10 10/10 (100)
6139B-RE active gene  8/11 1/11 2/11
pseudogene 0/11 0/11 11/11 (100)
All active L26 genes in 6139B-PRO are mutant, whereas pseudogenes are not. The presence or absence of an intron allowed this distinction.291 Beck-Engeser et al.
of the H→Y mL26 peptide in CFA. 7–8 d later, we deter-
mined the proliferative response of the lymph node cells
removed from these mice and restimulated in vitro by a
3-d culture with or without the peptide antigens. Fig. 3 B
shows that both peptides were immunogenic in vivo and
restimulated a specific proliferative immune response in
vitro. However, the P→S mL26 peptide required a several
fold higher antigen concentration to induce a similar prolif-
eration response than the H→Y mL26 peptide and was,
therefore, apparently less immunogenic.
Loss of Expression of the wt Allele of L9 during 6132A Tu-
mor Progression. One possible explanation for the reten-
tion of certain tumor antigens is that they are essential for
cell survival or the malignant phenotype. Our results above
show that the 6139B-PRO tumor no longer contains the
wt allele of L26. Since L26 is likely to be an essential com-
ponent of the ribosome (see Discussion), loss of the wt al-
lele would necessitate retention of the mutant proteins de-
spite their antigenicity. To explore the generality that the
wt allele of the gene encoding the retained antigen is lost,
we searched for loss of expression of the wtL9 allele in the
6132A tumors. Initial results using 5  PCR primers specific
for either the mL9 or the wtL9 cDNA together with a
common 3  PCR primer (Fig. 4 A), suggested that only
6132A-RE but not 6132A-PRO expressed the wt allele as
mRNA. A second tumor, 6132B, that had developed inde-
pendently at another skin site in the 6132 mouse, and HLFs
from the same mouse expressed only the wt allele (Fig. 4
A). Direct sequencing of cDNA by PCR from 6132A-
PRO tumor cells also suggested that the 6132A-PRO tu-
mor cells did not express the wtL9 mRNA, in contrast to
6132A-RE tumor cells and 6132-HLFs (6132-HLF; data
not shown). To confirm this observation, we analyzed a
quantitative reverse transcription (RT)-PCR of the two L9
mRNA species (Fig. 4 B) again using 5  PCR primers spe-
cific for either mutant or wtL9 cDNA with a common 3 
PCR primer. Again, mL9 was found to be expressed in the
6132A-RE and PRO tumor cells but not in normal 6132-
HLF. In contrast, wtL9 message was found in normal
6132-HLF and at lower levels in 6132A-RE cells; the
lower levels of wtL9 message in 6132A-RE may be due in
part to the simultaneous expression of the mL9 mRNA in
these cells, as one would expect if the total level of L9 mes-
senger RNA (wt and mutant) per cell were unchanged. In
addition, the 6132A-RE cells are mostly triploid (see be-
low) and may therefore have two mL9 alleles but only one
wt allele, thereby further reducing the wtL9 signal. In any
case, the observed lack of wtL9 expression in the 6132A-
PRO cells could not be accounted for by nonspecific inhi-
bition of the L9 wt-specific PCR primers by the 6132A-
PRO cDNA (Fig. 4 C). Thus, the 6132A-PRO tumor
cells express only the mutant but not the wt mRNA for
L9. By contrast, only wtL9 mRNA was present in PRO
variant cells of the unrelated tumor 6139B-PRO (Fig. 4 B),
in 6132B (Fig. 4 A) that developed as second independent
tumor in the 6132 mouse, and in 6132-HLF (Fig. 4, A and
Figure 3. (A) The 6139B-specific T cell hybridoma rec-
ognizes only the H→Y mL26 peptide (filled triangles), not
the wt peptide (filled squares) or the mutant P→S peptide
(filled circles). Antigenicity was measured by IL-2 secretion
using the MTT assay, as in previous figures. (B) Cells from
mice immunized with mL26 H→Y or P→S peptide in vivo
show a specific CD4  T cell response in vitro when restim-
ulated with the same L26 peptide that had been used in
vivo. Mice were injected into both hind footpads with a to-
tal amount of either 66 nmoles mL26 P→S peptide or 40
nmoles mL26 H→Y peptide emulsified in complete Freund’s
adjuvant. 7–8 d later mice were killed and their popliteal
lymph nodes removed. Cell suspensions were cultured for
3 d in the presence of either the peptide that had been used
for immunization in vivo, or the L26 peptide with the dif-
ferent mutation, or no peptide. Cells were pulsed on day 3
of culture with 1  Ci of [methyl-3H]thymidine and har-
vested 24 h later, the radioactivity measured in a liquid scin-
tillation counter. Three independent experiments are
shown. The L26 P→S peptide required a 4–8-fold higher
dose (100   g/ml) for similarly effective restimulation in
vitro than the L26 H→Y peptide (25 or 12.5  g/ml).292 Allelic Loss in Tumor Escape: Retention of Essential Mutant Antigens
B) derived from the mouse that gave rise to the 6132 tu-
mors. This pattern would be expected for a ubiquitously
expressed gene and a somatic mutation that caused a
unique (i.e., individually distinct) tumor-specific antigen.
The Gene Encoding the wt Allele of L9 Is Lost During Tumor
Progression in the 6132A Lineage. The absence of wtL9
transcripts in the 6132A-PRO tumor cells could be due to
either transcriptional silencing or loss of the wt gene. To
distinguish between the two alternatives, we analyzed an
allele-specific PCR using genomic DNA from 6132A-RE
and PRO cells and from 6132-HLF. We determined the
genomic structure of the murine L9 gene (unpublished
data) and designed a 3 -oligonucleotide primer that ampli-
fies an L9 gene fragment containing an intron. This al-
lowed us to distinguish the expressed L9 alleles from tran-
scriptionally silent L9 pseudogenes present in the murine
genome. As shown in Fig. 4 D, the mL9 gene was not
found in normal 6132-HLF, but was present in the 6132A-
RE and PRO tumor cells. The wtL9 allele was detected in
the 6132-HLF cells and the 6132A-RE cells. As observed
already for the mRNA signal in Fig. 4, A and B, the inten-
sity of the genomic wt signal was also weaker in the
6132A-RE tumor cells compared with 6132-HLF, for the
same possible reasons as listed above. In any case, no ge-
nomic wtL9-PCR fragment was amplified from 6132A-
PRO tumor cells, even though the same PCR primers effi-
ciently amplified the product from L9 pseudogenes (which
is smaller because it lacks introns; Fig. 4 D), thereby ex-
cluding a nonspecific inhibition of the PCR reaction in
these samples. Thus, the 6132A-PRO tumor cells have no
intact wt allele of the L9 gene.
Loss of wtL9 Allele by 6132A-PRO Cells Is due to its Dele-
tion from Chromosome 5. The absence of the wtL9 allele in
the 6132A-PRO cells could be due to either somatic re-
combination resulting in loss of the wt gene through re-
placement by a second mutant copy, or loss of the gene as a
result of a chromosomal abnormality, such as chromosome
loss or deletion. To distinguish between these two possibil-
ities, we analyzed FISH of metaphase cells from the 6132-
HLF, 6132A-RE, and 6132A-PRO lines. We first mapped
Figure 4. Retention of the mL9 gene and loss of the wtL9 gene by the 6132A-PRO variant. (A
and B) PCR analysis of L9 at the transcriptional level. RNAs from 6132A-RE or PRO tumor
cells, from untransformed fibroblasts from the mouse of tumor origin (6132-HLF), from a second
primary tumor that arose at a different site in this mouse 6132B), and from the unrelated UV-
induced tumor 6139B-PRO were analyzed by RT-PCR for the presence of mutant and wtL9
transcripts. The level of  -actin expression was used to normalize cDNA template amounts. PCR
reactions performed in the absence of cDNA (no cDNA) served to exclude carry-over contamina-
tions with genomic DNA, and reactions containing wt or mL9 encoding plasmid DNA were in-
cluded as specificity controls. Under restrictive PCR conditions, both primer sets were fully spe-
cific for their respective target sequences when either mutant or wtL9-encoding plasmid DNA was
used as a template. The mutation in L9 is somatic in origin since it is not found in normal control
cells (6132-HLF) from the mouse that developed the 6132A tumor. The mutation is individually
tumor-specific since it is not found in 6132B. (C) PCR analysis of L9 expression under nonrestric-
tive conditions using the same cDNAs and primer sets as in (B) shows that the apparent absence of
expression of wtL9 in 6132A-PRO did not result from nonspecific inhibition of the wtL9-specific
PCR primers, because the respective primer set did amplify mL9 cDNA from 6132A-PRO cells
under less stringent conditions. Furthermore, PCR reactions performed in parallel on cDNA syn-
thesized in the absence of reverse transcriptase (no RT) showed that the samples were not contam-
inated with genomic DNA. (D) Loss of the wtL9 gene in 6132-PRO cells. Genomic DNA from
6132A-RE and -PRO tumor cells and from 6132-HLF was used as template for PCR analysis with
mL9- or wtL9-specific primer sets. The upper arrow on the right (←genomic) indicates the ex-
pected size of the L9 alleles containing an intron, whereas the lower one (←pseudogenes) refers to
the intronless pseudogene PCR product. The numbers of base pairs (bp) on the left indicate the
sizes of the respective marker bands. No DNA: PCR control reactions performed in the absence of
DNA template. Note that the signal representing wtL9 expression by 6132A-RE appears to be re-
duced (A) and (B) as is the signal for the wtL9 gene (D), compared with the 6132A-HLF or other
control tumors (see text for explanation).293 Beck-Engeser et al.
the L9 gene to mouse chromosome 5, bands E1-E5 using
the human-mouse homology map (NCBI, and reference
34). To determine the number of chromosome 5 homo-
logues and copies of the L9 gene, we sequentially hybrid-
ized metaphase spreads with the L9 probe (reactive with
both wtL9 and mL9) and the chromosome 5-specific paint-
ing probe. A minimum of 20 metaphase cells were exam-
ined from each cell line. The 6132A-PRO cell line con-
tained two populations of cells. One population (8/20
cells) was diploid-hyperdiploid, each with 40–48 chromo-
somes and two chromosome 5 homologues per cell. The
second population (12/20 cells) was hypotetraploid-tetra-
ploid, and each cell contained four chromosome 5 homo-
logues. By FISH analysis with the L9-specific probe, only
one of the two chromosome 5 homologues was labeled in
the near-diploid population, whereas only two of four ho-
mologues were labeled in the tetraploid cells (Fig. 5). Thus
only 50% (32/64) of the chromosome 5 homologues of the
6132A-PRO tumor had the L9-specific signal. By contrast,
nearly all (52/58, 90%) of the chromosome 5 homologues
of the control 6132-HLF fibroblasts had the L9-specific
signal. Similarly, 85% (91/107) of all chromosome 5 ho-
mologues analyzed in 6132A-RE cells had the L9 signal.
The absence of a signal in minor fractions of chromosome
5 from control fibroblasts and 6132A-RE is most likely due
to low hybridization efficiency resulting from the relatively
small probe (a 2.3-kb genomic clone) and not due to loss of
the wt allele, as the fraction is similar (90 vs. 85% labeled
chromosome 5 homologues) in 6132 control fibroblasts
and 6132A-RE malignant cells.
Cytogenetic analysis of the 6132-HLF cell line revealed
a hypertriploid-tetraploid karyotype with 63–75 chromo-
somes. The majority of cells (14/20) had three chromo-
some 5 homologs, and the L9 hybridization signal was ob-
served on each of these; the remaining six cells had two of
these homologs labeled (five cells) or one of two homologs
labeled (one cell). The 6132A-RE cell line was character-
ized by increased karyotypic variability, with chromosome
numbers ranging from hyperdiploid to polyploid (45–131
chromosomes per cell). The number of chromosome 5 ho-
mologs ranged from 2–9 per cell, but the majority had
three (16/29 cells) or four (8/29 cells) copies. Of note was
that each homolog contained hybridization signal for the
L9 probe in the majority of cells (22/29). The absence of
signal on one of the chromosome 5 homologs in the re-
maining seven cells was most likely due to poor hybridiza-
tion efficiency.
These data suggest that loss of the wtL9 allele by 6132A-
PRO cells is the result of a small interstitial deletion en-
compassing the L9 gene. Combined with the data from ge-
nomic PCR analysis (Fig. 4 D), these findings indicate that
6132A-PRO has lost the wtL9 allele without loss of the
entire chromosome 5 homologue.
The wt but Not the mL9 Gene Suppresses the Growth of
6132A-PRO In Vivo. Since loss of heterozygosity during
tumor progression is a hallmark of genes that are function-
ally involved in the malignant process, loss of the wtL9
gene might have played an essential role in the progression
from 6132A-RE to 6132A-PRO. To test the hypothesis
that wtL9 acts as a tumor growth suppressor, we transfected
expression vectors containing wtL9 into 6132A-PRO cells
using mL9 as a control. Using conventional expression vec-
tors for initial attempts, we were never able to achieve the
high levels of expression characteristic of ribosomal pro-
teins. Therefore, we expressed both ribosomal proteins as
fusions with the EGFP in order to select transfectants with
high and comparable protein expression levels as assessed
by flow cytometry (Fig. 6 A). Examination of these trans-
fectants by fluorescence microscopy showed that the ribo-
somal–EGFP fusion protein, but not EGFP alone, localized
to the nucleoli, where ribosomes are assembled (Fig. 6 B).
In other experiments, cells transfected with cDNA for an
wtL9-EGFP were lysed, the ribosomes isolated by sucrose
gradient ultracentrifugation, and analyzed by Western blot
analysis using an anti-EGFP antibody. These Western blot
analysis clearly demonstrated incorporation of the fusion
protein into ribosomes (Spiotto, M., unpublished data).
Most of the 6132A-PRO transfectants had a similar or
somewhat faster growth rate than untransfected 6132A-
PRO cells in vitro (data not shown). To assess growth rates
in vivo independent of immune responses, we injected
transfected cells into SCID mice. We have previously
shown that when particular numbers of tumor cells are in-
jected, 6132A-RE cells grow very slowly in T cell–defi-
Figure 5. In situ hybridization of a genomic L9 probe and a chromo-
some 5-specific painting probe to 6132A-PRO cells. Only two of the
four chromosome 5 homologues present in near-tetraploid cells from
6132A-PRO cells show a hybridization signal for L9 (arrows); the unla-
beled homologues are identified with arrowheads. Hybridization of the
biotin-labeled L9 probe was detected with fluorescein-conjugated avidin
(yellow-green signal), and the digoxigenin-labeled chromosome 5 paint-
ing probe was detected with rhodamine-conjugated, anti-digoxigenin an-
tibodies (red signal). Images were obtained using a Zeiss Axiophot micro-
scope coupled to a cooled-charge, coupled device camera. Separate
images of DAPI-stained chromosomes, the L9 hybridization signal, and
the painting probe signal were merged using image analysis software
(NU200 and Image 1.57).294 Allelic Loss in Tumor Escape: Retention of Essential Mutant Antigens
Figure 6. Reduced growth of 6132A-PRO cells that have been transfected to reexpress the wtL9 gene. (A) Expression levels of the transfected wt or
mutant fusion genes as analyzed by flow cytometry. Fluorescence of EGFP is shown on the x axis for tumor cells either untransfected (6132A-PRO) or
transfected with EGFP alone (E-PRO) or fusions of EGFP with wtL9 (wtL9-E-PRO) or mL9 (mL9-E-PRO). (B) Microscopic analysis of 6132A-PRO
cells transfected with the EGFP gene alone or with a fusion gene of EGFP and mutant or wtL9. Fusing EGFP to L9 (bottom left and bottom right pho-
tographs) leads to a cellular distribution of the fusion protein that is characteristic for a ribosomal protein (i.e., nucleoli are stained), whereas unfused
EGFP (top right photograph) does not show a specific localization. (C) 6132A-PRO cells transfected to reexpress wtL9 (wtL9-E-PRO) (bottom panel)
grow as slowly as untransfected 6132A-RE cells (top panel) (RE) in C3H SCID mice. 6132A-PRO transfected with either EGFP alone (E-PRO) or (top
panel) mL9-EGFP (mL9-E-PRO) (bottom panel) both have a more rapid growth rate. All cell lines shown were tested concurrently but are shown in the
two panels to reduce overlap of lines. SCID mice were inoculated subcutaneously with 3   105 tumor cells. Tumor volume was determined using a cal-
iper and the formula for the volume of an ellipsoid ( /6   abc, where a, b, c are orthogonal diameters). (D) Similar results were consistently obtained us-
ing independent transfectants and experiments. Growth of 6132A-PRO cells expressing mL9-EGFP, injected subcutaneously into opposite flanks of the
same SCID mouse was compared. Each panel represents results of one mouse. Even though individual SCID mice differ in their relative ability to sup-
port the growth of tumor inocula, the wtL9-expressing tumor cells always formed tumors much more slowly than did those expressing mL9-EGFP.295 Beck-Engeser et al.
cient mice, whereas 6132A-PRO cells grow quickly in
such mice (24). Fig. 6 C shows that 6132A-PRO cells
transfected to express wtL9-EGFP grew in SCID mice
as slowly as 6132A-RE cells tested concurrently, while
6132A-PRO cells transfected to express EGFP alone or
mL9-EGFP grew at a significantly higher rate, and this was
observed in several independent experiments using inde-
pendent transfectants (Fig. 6 D). When threefold to 100-
fold lower tumor cell numbers were used for challenge,
6132A-PRO cells transfected to express wtL9-EGFP failed
to form tumors. Likewise, no tumors were obtained after
inoculating the SCID mice with 6132A-RE cells at this tu-
mor cell number. In marked contrast, SCID mice inocu-
lated with 6132A-PRO cells transfected to express EGFP
had already formed large tumors at a comparable time point
(Table III). Thus, expression of wtL9 specifically inhibited
or prevented the growth of 6132A-PRO cells in vivo.
These observations suggest that loss of the wtL9 allele dur-
ing tumor progression contributed to the transition from
6132A-RE to -PRO. Since this growth inhibition in vivo
is apparent in SCID mice, it is independent of functional T
or B cell immunity and also not influenced by the immu-
nogenicity of EGFP.
Discussion
In this paper, we have studied two tumor-specific anti-
gens, recognized by CD4  T cells, that were retained by
tumors as they evolved from RE to PRO in vivo (12, 24).
In both of the UV light-induced tumors analyzed (6132A
and 6139B), the retained antigens are point-mutated ribo-
somal proteins (L9 and L26, respectively). In both tumors,
the wt alleles have been lost during tumor progression. In
the case of 6132A, the wtL9 allele was lost in the transition
from RE to PRO by an interstitial deletion in chromo-
some 5, as shown by loss of a signal for the gene by FISH.
In the case of 6139B, the two alleles of L26 have different
point mutations (position 22P→S and position 96H→Y),
with no wt allele remaining; these changes may already be
complete in the parental RE tumor. The aggressive growth
phenotype of 6132A-PRO could be reversed to that of the
parental RE by transfection with wtL9-EGFP, but not by
transfection of mL9-EGFP or EGFP alone. We will argue
below that these findings (mutant ribosomal proteins and
loss of the wt alleles) have implications relevant to elucidat-
ing the reasons that some highly immunogenic mutations
are retained: first, the mutant proteins are likely to be es-
sential for cell growth and function and loss of the normal
alleles makes the associated antigens difficult to lose. Sec-
ond, the observations of allelic loss are consistent with the
possibility that the wtL9 and L26 genes serve as tumor
growth suppressors, mutation or loss of which contributes
to tumor progression, and this is suggested by our results
with reintroduction of wtL9 into 6132A-PRO.
Relatively little is known about the precise roles of the
 50 proteins comprising about one-third of the mass of
the ribosome, but it is clear that assembly of new ribosomes
and thus synthesis of ribosomal proteins is an essential first
step after growth factor stimulation to allow proliferation
(35). Ban et al. (36) proposed, based on 2.4A resolution
crystal structure, that ribosomal proteins function as “mor-
tar,” filling cracks and gaps between RNA “bricks,”
thereby principally serving to stabilize RNA structure.
Even though RNA, not protein, appears to be responsible
for the catalytic activity of the ribosome (36), complete
deproteination destroys this activity (37), so these building
materials appear to be essential. In addition, there is evi-
dence that L9 and L26 also have important regulatory func-
tions. Bacterial L6, the prokaryotic homologue of L9, is
one of the most highly conserved ribosomal proteins (38)
and is located at the binding site of elongation factor (EF)-2,
which contains the sarcin-ricin loop. EF-2 and the ricin
Table III. Reversion to a RE Phenotype of 6132A-PRO Cancer Cells After Reexpression of the wtL9 Protein
Size of tumor cell inoculum
103 cells 3   103 cells
Tumor cells Transfected gene Tumor incidence  Tumor volume Tumor incidence Tumor volume
(cm3) (cm3)
6132A-PRO EGFP 3/3 1.4   0.7 3/3 2.0   0.7
wtL9-EGFP 0/3 0 0/3 0
6132A-RE EGFP 0/3 0 0/3 0
6132A-PRO tumor cells were transfected with a vector encoding the EGFP or EGFP fused to the wtL9 protein (wtL9-EGFP). 6132A-RE cells
transfected with the gene encoding EGFP only were used as control representing cells of the RE phenotype. The three cell lines were injected into
three different dorsal subcutaneous locations of C3H SCID mice at one of the two different doses as indicated. Final tumor volumes were calculated
using the formula  /6   abc, where a, b, and c are orthogonal diameters using measurements at day of killing, 28 d after injection with 105 cells or
52 d after injection with 3   103 tumor cells. All tumors that were detected at time of sacrifice were isolated and found to have retained expression
of EGFP as analyzed by flow cytometry.296 Allelic Loss in Tumor Escape: Retention of Essential Mutant Antigens
A chain have been cross-linked to eukaryotic L9 (39, 40).
Phosphorylation of eukaryotic S6, which follows stimula-
tion of cells with nutrients or growth factors (35, 41, 42)
results in the translational upregulation of 5  track of py-
rimidines (TOP) mRNAs (43) which encode most riboso-
mal proteins and elongation factors. L9 is conformationally
changed after phosphorylation of S6 (44) and this change
may be essential for the formation of new ribosomes. mL9
may act as a constitutively active form permitting ribosome
neogenesis in the absence of growth factors whereas the in-
active wt configuration may not allow this, thereby acting
as a growth suppressor. Interestingly, a somatic tumor-spe-
cific point mutation in EF-2 was found to be the target of a
CD8  T cell response to a human squamous cell lung car-
cinoma (45), and it is tempting to speculate that this muta-
tion contributed to tumor growth by affecting a similar
pathway as mutation of L9 in our study.
The prokaryotic homologue of L26, L24 is one of the
two assembly initiator proteins of the large ribosomal sub-
unit (46) and appears to play a key role in the folding and
organization of the 23S rRNA early in ribosome assembly
(47), an essential first step for any cell proliferation. Prokary-
otic L24 has also been shown to encircle the exit of the
polypeptide exit tunnel of the large ribosomal subunit (36).
The location of eukaryotic L26 in the large subunit has not
yet been reported; earlier cross-linking studies had suggested
that both eukaryotic L26 and L9 bound to the same protein,
L4, but this is not supported by the crystallographic studies
of the prokaryotic ribosomal subunit (36). Thus, we have
less of a hint about possible growth regulation by L26; such
a function need not occur in the ribosome, however, as
other ribosomal proteins have been shown to have other
functions elsewhere in the cell (48–56).
Mutation of one allele of a regulatory gene, followed by
inactivation of the second allele by loss (as we observe with
L9) or mutation (as we observe with L26), is a pattern char-
acteristic of the alteration in tumor suppressor genes that
occurs during development of cancer, the “two hit” hy-
pothesis proposed by Knudson (57). Our finding that the
reintroduction of wtL9 into 6132A-PRO cells causes re-
version to the growth characteristics of the RE tumor
identifies L9 as a tumor growth suppressor. In contrast to
classic tumor suppressor genes, however, wtL9 appears to
slow the rate of tumor growth, likely through interaction
with host factors (the slower growth being apparent only in
vivo, in the absence of T cell immunity), rather than sup-
pressing malignancy per se. The growth suppressive effect
of reexpressing the wtL9 by the transfected 6132 cells may
be detectable in vivo only because in vivo growth factors
are limiting and the tumor cells may be more susceptible to
this growth regulation than tumor cells growing in vitro
where FCS provides for an abundance of growth factors. In
any case, the conclusions that can be reached by our tumor
suppressor experiments are only preliminary because of the
possibility that fusing EGFP to the wt protein might alter
the function of the L9 molecule. More detailed examina-
tion of this function will require “knockout” and “knock-
in” of L9 alleles, to determine the phenotype of 6132A-RE
cells in which either wtL9 or mtL9 is eliminated, as well as
exploration of the effects of different ratios of normal and
mL9 expression.
Independent of the specific roles of wt or mL9 and L26
in ribosomal function, several lines of evidence suggest
that their expression is essential to the function of any
cell. Both proteins or their respective prokaryotic homo-
logues L6 and L24 are found in ribosomes throughout
evolution. Homozygous disruption of the L9 gene in
Drosophila is lethal, and heterozygous disruption is associ-
ated with a minute phenotype (9). Minutes are a group of
 50 phenotypically similar mutations in Drosophila, char-
acterized by generally retarded development, infertility,
and recessive lethality (58). Mapping studies suggest that
these mutations affect genes for ribosomal proteins; where
the disrupted loci have been characterized in detail, all
have indeed been found to encode ribosomal proteins.
Further evidence suggests a similar importance for riboso-
mal alleles in mammals, including humans. First, it has
been proposed that the Turner Syndrome (monosomy X)
in humans, characterized by short stature, developmental
abnormalities of the heart, kidney, and skeleton, infantile
genitalia, and infertility, may be caused in part by loss of
an allele of the X chromosome–encoded isoform of ribo-
somal protein S4, analogous to the heterozygous minute
phenotype in Drosophila (52, 59). Second, the effects of
conditional homozygous deletion of a ribosomal protein
in adult liver tissue have been tested in mice; deletion of
S6 did not immediately kill liver cells, but it prevented
the formation of new ribosomes and abrogated any regen-
erative proliferation of the hepatocytes after partial hepa-
tectomy (35).
These data argue strongly that a cell, even a tumor cell,
could not lose expression of a ribosomal protein and con-
tinue to be able to proliferate. In 6132A-PRO and 6139B
(-RE or -PRO), the tumors express only mutant alleles of
the L9 and L26 proteins, respectively. Since the mutations
are immunogenic, these tumors contain antigens that can-
not be lost, short of highly improbable reversion point mu-
tations to the wt (which may also reinstate a tumor growth
suppressor effect), as a means of escaping from host immu-
nity. If analogous antigens were to be found on human tu-
mors, they would serve as ideal targets for immunotherapy.
Although the existence of such antigens in humans is hypo-
thetical, other classes of tumor-specific point mutations
originally found in mice, such as mRNA helicases, have
subsequently been found also in human cancers (60). Our
findings thus support a search for mutant ribosomal pro-
teins in human cancers. In the meantime, the generalizabil-
ity of some of our findings is suggested by the recent dis-
covery that a CD4  T cell recognized antigen on the
methylcholanthrene-induced tumor MethA is a point-
mutated L11 ribosomal protein (61). MethA was induced
in 1962 and is, by comparison with our UV-induced tu-
mors, already highly aggressive. Variants representing stages
of malignant progression are, therefore, not available. Since
the wtL11 allele was retained, MethA cells might be able to
lose the mL11 antigen unless it played a role in maintaining297 Beck-Engeser et al.
malignant behavior. A broader search for immunogenic ri-
bosomal proteins could be undertaken by immunizing
mice with ribosomes from a variety of tumors.
The UV-induced RE tumors such as 6132A-RE or
6139B-RE that are rejected by syngeneic normal recipients
grew in the primary hosts because UV is not only carcino-
genic but also immunosuppressive in mice (62). This con-
clusion is supported by the fact that the RE tumors can
grow, at least slowly, in UV-irradiated and T cell–deficient
hosts (24). Other factors, such as an inherent growth ad-
vantage that primary tumors have over transplanted tumors
and the advanced age of the host developing primary UV-
induced RE tumors, may also be essential and contribute.
Of course, the importance of the observation that an anti-
gen is retained during tumor progression depends on its
role in immunity. Our previous studies have shown that
CD4  cells are dispensable for rejection of either 6132A or
6139B by normal mice, whereas CD8  cells are essential
(12, 26). However, we have subsequently found that
CD4  cells can be essential to resist a tumor cell challenge,
that CD4  clones and lines are highly effective in eliminat-
ing 6132A-PRO cells in vivo in the absence of CD8  cells,
and that immunization with purified L9 antigen affects the
subsequent growth of 6132A in normal mice (3, 20, and
unpublished data). Antigens retained on the 6132A- and
6139B-PRO tumors can still be rejection antigens. 6132A-
PRO and 6139B are still immunogenic tumors, growing
progressively in only  50% of normal mice even when
transplanted as tumor fragments, and essentially never
when implanted as cultured cells (while growing regularly
when implanted as cells or fragments into T cell–deficient
mice). The ability of 6132A-PRO to grow progressively at
all in immunocompetent mice, and therefore its difference
from 6132A-RE, appears to depend on a greater sensitivity
of the PRO variant to growth stimulation by host cells (24,
25). In many other models, loss of MHC class I antigens
has also been shown to be an effective way for a tumor to
escape from immunity (63). Such a finding could be devas-
tating for the development of durable immunotherapy of
cancer, because cancer cells can lose MHC expression
without perturbation of cell function. However, we (20)
and others (18, 19) have shown that tumor cell killing by
CD4  cells in vivo is independent of expression of MHC
class II molecules by the tumor cells. Thus, the existence of
antigens that cannot be easily lost, due to their essential
functions in the physiology of the cancer cell, is particularly
relevant when considering antitumor immunity of CD4 
T cells.
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